IL2 and breast cancer: In-situ studies of TIL in breast cancers demonstrate expression of the early activation markers CD38, 43 and 69, but show little or no expression of IL-2 receptor or IL-2 protein (Coventry et al, 1996), suggesting anergic, tolerant T-cells.